Clinical implementation of first trimester pre-eclampsia screening
Available now on-demand! Duration: 1,5 h
The presentation focus will be on clinical implementation of first trimester pre-eclampsia screening in different set-ups and countries. You will have the possibility to interact live with 5 of the most outstanding professionals in prenatal screening and address your questions directly to the experts.
A Certificate of Attendance will be sent to participants.
Agenda
Welcome from Chairman Prof. Kevin Spencer Former Consultant Biochemist & Clinical Lead, Kings George Hospital, London, UK
Ultrasound aspects and implementation in Hong Kong Dr. Liona Poon Professor (Clinical), Prince of Wales Hospital, Hong Kong
Lab perspective and implementation in Toulouse Dr. Safouane Hamdi Assistant-Professor of Hormonology and Senior Researcher at the Research Group on Human Fertility Toulouse University, France
Health economic aspects and implementation in Dresden Prof. Cahit Birdir Head of Obstetrics and Prenatal Medicine, Universitätsfrauenklinik Dresden, Germany
Implementation and effectiveness of early PE screening in London Prof. Basky Thilaganathan Professor in Fetal Medicine and Consultant Obstetrician and Director, Fetal Medicine Unit St Georges, St George’s Hospital, London, UK
Pre-eclampsia management throughout pregnancy in times of COVID-19
The webinar held on June 17th, 2020 at 4:00pm CET
This webinar provided the latest scientific information on pre-eclampsia screening and its management throughout pregnancy – especially in the current period of COVID-19.
Speakers
Dr. C. Birdir, University Hospital Dresden, Germany Implementing first trimester pre-eclampsia screening in a model region in Germany
9th International Workshop on Prenatal Screening - Berlin 2017
We are very pleased to share most of the lectures as pdf files and videos.
Ensuring high quality NIPT
There is a lack of external quality control scheme for cfDNA prenatal tests. Dr. Deans, the scheme director of UK NEQAS, introduces the EQA pilot project.
Prof. Dr. Tercanli shares experience of cfDNA and contingent screening implementation in Switzerland, discusses results and learnings for the last year.
Dr.Gil presents FMF studies about performance of cfDNA/NIPT test, screened conditions, interpretation of results and a model of clinical implementation.
Prof. Kagan describes a first trimester screening approach in weeks 11-13 to detect pregnancy complications as trisomies, preeclampsia, IUGR, preterm birth.
Not all products are CE marked or have 510(k) clearance for sale in the U.S. Availability of products in each country depends on local regulatory marketing authorization status.
Dr. C. Birdir, University Hospital Dresden, Germany
Prof. S. Verlohren, Charité Berlin, Germany